| Code | CSB-MP008543HU1 |
| Abbreviation | Recombinant Human FCGR3A protein, partial (Active) |
| MSDS | |
| Size | $110 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
CD16a mediates antibody-dependent cellular cytotoxicity by bridging IgG-opsonized targets to natural killer cells and macrophages, making it a critical node in therapeutic antibody efficacy and immune surveillance studies. This mammalian-expressed construct spanning residues 17–208 captures the complete extracellular ligand-binding domain, preserving the native glycosylation and disulfide architecture required for physiologically relevant Fc interactions. Functional ELISA validation demonstrates specific antibody binding with an EC50 of 0.233–0.315 ng/mL, confirming conformational integrity suitable for therapeutic antibody epitope mapping, competitive inhibition screening of ADCC-modulating biologics, and SPR-based affinity characterization of Fc-engineered variants. The protein meets quality thresholds commonly required for ligand-binding assays and blocking antibody development, with purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg to support cell-based functional studies where low endotoxin burden is essential for accurate readouts of NK cell activation and cytotoxicity.
There are currently no reviews for this product.